Synthetic antagonists of lipopolysaccharide (LPS) are currently being evaluated as a treatment for septic shock in humans. 1 Two of these antagonists, E5531 and E5564, are potent and highly purified synthetic lipid A analogs that have been shown to inhibit LPS-stimulated responses in cell-based assays, and to prevent both LPS-induced lethality in mice, and cytokine release in an animal model of sepsis. 2 Based on previous studies, it is believed that E5531 antagonizes LPS activity at its cell-surface receptor, leading to inhibition of transmembrane signal transduction. [3] [4] [5] 18 Expression of a functional Toll-like receptor 4 (TLR4) pro-tein is critical for sensitive physiological responses to LPS, which is evident in the spontaneous TLR4 mutant mice (C3H/HeJ and C57/10ScCr) and TLR4 knockout mice. 6, 7 We discovered that E5531 inhibits the stimulation of TLR4-transfected cells by LPS in a dose-dependent manner, with an IC 50 of ~30 nM, 5 suggesting that the LPS antagonists target TLR4. In contrast, E5531 did not affect interleukin-1β (IL-1β) activation of nuclear factor-κB in TLR4-transfected cells 5 or the actions of interferon-γ in murine macrophages, 2 indicating that the inhibitory activity of E5531 is specific for cell-surface components utilized by LPS. Recently, the activity of a novel synthetic acyclic lipid A agonist of the TLR4 pathway was blocked by the LPS antagonist E5564 in the absence of membrane-bound or soluble CD14, further supporting our hypothesis that these antagonists may interact with the LPS receptor. 18
INTRODUCTION
Synthetic antagonists of lipopolysaccharide (LPS) are currently being evaluated as a treatment for septic shock in humans. 1 Two of these antagonists, E5531 and E5564, are potent and highly purified synthetic lipid A analogs that have been shown to inhibit LPS-stimulated responses in cell-based assays, and to prevent both LPS-induced lethality in mice, and cytokine release in an animal model of sepsis. 2 Based on previous studies, it is believed that E5531 antagonizes LPS activity at its cell-surface receptor, leading to inhibition of transmembrane signal transduction. [3] [4] [5] 18 Expression of a functional Toll-like receptor 4 (TLR4) pro-tein is critical for sensitive physiological responses to LPS, which is evident in the spontaneous TLR4 mutant mice (C3H/HeJ and C57/10ScCr) and TLR4 knockout mice. 6, 7 We discovered that E5531 inhibits the stimulation of TLR4-transfected cells by LPS in a dose-dependent manner, with an IC 50 of ~30 nM, 5 suggesting that the LPS antagonists target TLR4. In contrast, E5531 did not affect interleukin-1β (IL-1β) activation of nuclear factor-κB in TLR4-transfected cells 5 or the actions of interferon-γ in murine macrophages, 2 indicating that the inhibitory activity of E5531 is specific for cell-surface components utilized by LPS. Recently, the activity of a novel synthetic acyclic lipid A agonist of the TLR4 pathway was blocked by the LPS antagonist E5564 in the absence of membrane-bound or soluble CD14, further supporting our hypothesis that these antagonists may interact with the LPS receptor. 18 The synthetic antagonists of lipopolysaccharide (LPS), E5531 and E5564, are analogs of the lipid A portion of LPS that not only lack agonistic activity but also inhibit the biological effects of LPS both in vitro and in vivo. The effects of LPS and these synthetic antagonists have been localized to the recently described Toll-like receptor 4 (TLR4). A recent report indicated that the naturally occurring LPS antagonist Rhodobacter sphaeroides LPS loses its antagonist properties and gains proinflammatory qualities in the presence of chlorpromazine and other amphipathic drugs. To determine whether these reported actions occur with our chemically defined LPS antagonists, we examined the effects of chlorpromazine, fluphenazine, trifluoperazine, and lidocaine on the antagonism elicited by RsLPS and E5531 in U373 cells, which produce IL-6 in response to LPS. We also tested the effects of these amphipathic molecules on the LPS-neutralizing activity of RsLPS and E5564 on LPS-induced TNF-α release in human whole blood. The results indicate that neither chlorpromazine, fluphenazine, trifluoperazine nor lidocaine alter the activity of E5531 or E5564 in an in vitro cell system or human whole blood. Furthermore, chlorpromazine did not affect the antagonistic activity of RsLPS or E5564 on IL-6 generation by peripheral blood mononuclear cells. Thus, based on these data, our purified synthetic LPS-antagonists do not appear to lose their antagonistic properties and/or become agonists in the presence of amphipathic agents or drugs.
Thieblemont et al. reported the effects of small molecule amphipaths on the cellular responses induced by LPS, the natural LPS antagonist Rhodobacter sphaeroides LPS (RsLPS), and its fragment Rh. sphaeroides lipid A (RsLA). 8 It was reported that the antagonistic action of RsLPS on LPS uptake, IL-6 generation in peripheral blood mononuclear cells (PBMCs), and adherence of polymorphonuclear neutrophils were eliminated in the presence of chlorpromazine (CPZ) and other amphipathic molecules. Instead, RsLPS and RsLA were transformed from LPS antagonists to full LPS mimetics in the presence of these amphipaths. 8 Such extraordinary reversal of activity prompted us to investigate the effects of these reported amphipaths on the ability of E5531 or E5564 to antagonize LPS actions in U373 cells, whole blood, and PBMCs.
MATERIALS AND METHODS

Materials
U373 cells were obtained from American Type Culture Collection (Rockville, MD, USA). LPS and RsLPS were purchased from List Biologicals. Chlorpromazine, trifluoperazine, lidocaine, and fluphenazine were from Sigma Chemical Co. (St Louis, MO, USA). The LPS antagonists E5531 and E5564 were synthesized as described. 2 The purity of these compounds was found to be greater than 99% as assessed by standard analytical methods. LPS, RsLPS, and antagonists were dissolved in sterile pyrogen-free water and stored at -20°C. Soluble CD14 (sCD14) was purified from Chinese hamster ovary -K1 cells expressing human CD14 as described. 5 
IL-6 generation in U373 cells
U373 cells were maintained in MEM supplemented with 10% FBS, L-glutamine, non-essential amino acids, sodium pyruvate, and antibiotics. Cells were seeded in 96-well plates at a density of 20,000 cells/well, and allowed to adhere to the plates overnight. Serum-containing medium was removed, the cells were washed 3 times with Hank's balanced salt solution, and replaced with serum-free media. The indicated compounds, antagonists, and/or LPS plus sCD14 (10 nM) were incubated with the cells for 6 h at 37°C. Culture supernatants were assayed for human IL-6 by ELISA kit per the manufacturer's recommendations (Endogen, Woburn, MA, USA).
TNF-α generation in human whole blood
Blood was collected aseptically from 18-50-year-old, normal male and female volunteers into sterile tubes containing heparin (20 U heparin/ml blood; Abbott Laboratories, N. Chicago, IL, USA). Aliquots of heparinized blood (400 µl) were added to 48-well plastic tissue culture plates (Gibco Laboratories, Grand Island, NY, USA) followed by addition of compounds, antagonists, and/or LPS. The plates were then incubated for 3 h at 37°C, 5% CO 2 on an orbital shaking platform (Bellco Technology Inc., Vineland, NJ, USA). After incubation, the plates were centrifuged (1000 g, 10 min, 4°C); plasma supernatants were removed and then frozen at -80°C. Plasma samples were assayed for TNF-α using the human Quantikine TNF-α ELISA kit (R & D Systems, Minneapolis, MN, USA).
Data are shown as mean ± SE for one representative experiment or blood donor performed in triplicate. In the figures, each experiment was repeated three times with either different cell platings or blood donors.
IL-6 generation by PBMCs
These experiments were performed as described by Thieblemont et al. 8 Heparinized blood was obtained by venipuncture from healthy volunteers and PBMCs were separated by density centrifugation with Histopaque (Sigma Chemical Co.). The buffy-coat layer containing mononuclear cells was removed and washed with Dulbecco's PBS and resuspended in RPMI supplemented with L-glutamine, and antibiotics. For each subject, 2% heat-inactivated autologous plasma was added to the resuspended cell preparation. Cells were seeded in 96-well plates at a density of 50,000 cells per well and the indicated compounds, antagonists, and/or LPS plus CD14 were added and incubated for 5 h at 37°C. Culture supernatants were obtained by centrifuging for 5 min at 12,000 rpm and were stored at -20°C until assayed for IL-6 using a human IL-6 ELISA (Endogen, Woburn, MA, USA) as per the manufacture's recommendations. LPS and antagonists were complexed with sCD14 prior to addition to PBMCs by incubating 100 µg/ml sCD14 with either 5 µg/ml LPS or RsLPS or 1 µM E5564 for 16 h at 37°C. Data are shown as mean ± SE of triplicate measurements from 4 donors per treatment group.
RESULTS AND DISCUSSION
U373 human glioblastoma cells respond to LPS in the presence of sCD14 by producing IL-6, which is released into the culture medium. 9 The amount of sCD14 in the medium modulates the ability of LPS to stimulate IL-6 production by U373 cells (Fig. 1) . Such response was antagonized by co-incubation of LPS with the lipid A antagonists E5531 and E5564, in a dose-dependent manner (Fig. 2) , consistent with previous observations in monocytes and macrophages. 2 These observations support the hypothesis that E5531 blocks the interaction of LPS/CD14 and TLR4, as U373 cells express significant quantities of TLR4. 10 However, it remains to be determined whether LPS or this LPS antagonist can physically associate with TLR4.
We first examined the effects of chlorpromazine on E5531 activity to determine the effects of the reported amphipaths on the ability of the antagonist to alter LPS actions. The results demonstrate that E5531 inhibited LPS/sCD14-induced stimulation of IL-6 synthesis in U373 cells regardless of whether chlorpromazine (100 nM) was present or not (Fig. 3A) . This concentration of chlorpromazine was chosen based on the report that 50-500 nM chlorpromazine stimulates maximal IL-6 release by RsLPS-treated PBMCs. 8 Furthermore, neither E5531 nor RsLPS had any IL-6 stimulatory activity in the presence or absence of chlorpromazine ( Fig. 3) . We also tested the effects of other amphipaths that inverted the [Compound] (nM) IL-6 production (pg/ml) Fig. 2 . E5531 or E5564 inhibits LPS-stimulated IL-6 production by U373 cells. Cells were cultured and plated as described in Materials and Methods. The next day, the indicated concentration of E5531 or E5564 was added to the serum-free medium in the presence or absence of LPS (100 ng/ml) and sCD14 (10 nM) for 16-18 h. Aliquots of cell medium were assayed for human IL-6 as described in Materials and Methods. Each point represents the mean ± SE of triplicate measurements and the result is representative of three independent experiments. Each point represents the mean ± SE of triplicate measurements and the result is representative of three independent experiments.
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antagonistic activity of RsLPS in the study by Thiebelmont et al. 8 in these cells. As shown in Figure 3B , fluphenazine, trifluoperazine or lidocaine did not affect the LPS antagonistic action of E5531 or RsLPS in U373 cells. In addition, the amphipaths did not alter the stimulatory effects of LPS/ sCD14 on IL-6 production ( Fig. 3B) . While the experiments shown in Figure 3B were performed at 100 nM, even concentrations up to 10 µM had no discernible effect on the LPS antagonistic qualities of E5531 (data not shown).
In addition to these experiments with the U373 cells tested in serum-free medium, the effects of chlorpromazine, fluphenazine, trifluoperazine, and lidocaine were also tested in human whole blood in the presence of E5531 or E5564. Under these conditions, human monocytes are believed to respond to LPS in an LBP-enhanced CD14dependent manner, presumably as a result of TLR4 engagement. 11 Similar to the experiments with U373 cells, chlorpromazine (100 nM) did not influence the antagonistic Each bar represents the mean ± SE of triplicate measurements from 4 donors. effects of E5564 on LPS-induced TNF-α production at several concentrations of inhibitor (Fig. 4A ). Furthermore, none of the four amphipaths had any LPS-mimetic effect on TNFα release in the presence of either 1 µM E5531 (Fig. 4B ), E5564 or RsLPS (data not shown) in human whole blood. Consistent with these findings, chlorpromazine did not alter the activity of RsLPS or E5564 on IL-6 generation in human PBMCs (Fig. 5 ) performed as described by Thieblemont et al. 8 However, despite the lack of agonistic activity in the presence of chlorpromazine, both RsLPS and E5564 blocked IL-6 production by PBMCs, indicating that these compounds are effective antagonists of LPS effects (Fig. 5,  inset) .
The results presented here indicate that chlorpromazine and other amphipathic drugs do not reverse the activity of E5531, E5564 or RsLPS from antagonist to agonist in two different cellular assays: (i) U373 cells, an LPS-responsive cell line cultured under serum-free conditions; and (ii) human whole blood, a system comprised of a heterogenous population of LPS-responsive cells in plasma. The lack of effect of these amphipathic drugs on the activity of RsLPS in these assays is not consistent with the study by Thieblemont et al. 8 performed with isolated human neutrophils and monocytes cultured in highly defined medium.
We attempted to reproduce the effect of chlorpromazine on RsLPS activity in PBMCs as described by Thieblemont et al. 8 (Fig. 5 ). CPZ (500 nM) did not alter the LPS-antagonistic activity of either RsLPS or E5564 in PBMC under identical conditions as described 8 using blood samples from four different donors. At this time, the reason for this discrepancy is not clear, but perhaps different preparations of RsLPS contain more than one molecular variant or impurities that exhibit agonistic behavior in the presence of these amphipathic drugs. An example of the difficulties of working with lipid A-like molecules is that many of these compounds are sensitive to storage conditions. Others and ourselves have found that the naturally derived RsLA or the synthetic version of the predicted structure of RsLA 15 is susceptible to degradation upon standing in solution, which appears to generate potent LPS mimetics (unpublished observations and Golenbock D., personal communication).
Furthermore, Thieblemont and colleagues 8 speculated that the amphipaths may partition into membranes and alter lipid transport mechanisms by allowing RsLPS to internalize into the cell, a phenomenon that otherwise does not occur in the absence of amphipaths. However, CPZ and lidocaine do not partition into membranes at nanomolar concentrations. 12 Instead, Sheetz and Singer reported that partitioning occurs at concentrations in excess of 100 µM, which is significantly higher than the range (5-500 nM) of chlorpromazine used in the Thieblemont study. 8 Therefore, it is not clear as to the mechanism by which amphipaths alter RsLPS activity in vitro. Moreover, increasing evidence in the Toll-like receptor field suggest that the signaling properties of LPS are mediated by the direct binding of ligands to transmembrane proteins and not via a lipid transport mechanism/endocytosis. 13, 14 Recent studies have demonstrated that TLRs and proximal signaling proteins commonly utilized by IL-1 and IL-18 mediate LPS-induced responses. 16, 17 We have shown that LPS and our antagonists require the presence of TLR4 in order to exert their actions on otherwise unresponsive cells. 4 In summary, these data clearly demonstrate that the antagonistic activities of E5531 and/or E5564 do not invert when tested in U373 cells under serum-free conditions human whole blood, or PBMCs.
